Glaukos Corporation (NYSE:GKOS – Get Free Report) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $190.06 and last traded at $189.7240, with a volume of 505111 shares changing hands. The stock had previously closed at $184.15.
Key Stories Impacting Glaukos
Here are the key news stories impacting Glaukos this week:
- Positive Sentiment: BTIG Research raised its price target to $202 from $193 and maintained a “Buy” rating. The new target implies further upside and reflects confidence in Glaukos’ growth outlook. BTIG price target report
- Positive Sentiment: Zacks Research increased several earnings forecasts, including FY2026 EPS to a loss of $0.43 from a loss of $0.65, Q3 2026 EPS to a loss of $0.13 from $0.16, and Q4 2026 EPS to positive $0.03 from a loss of $0.02. Longer-term estimates were also raised to $0.45 EPS for FY2027 and $1.70 for FY2028, supporting expectations for a transition to profitability. Zacks analyst estimates
- Positive Sentiment: Investor interest remains focused on momentum from the iDose TR glaucoma implant, the Epioxa launch, higher 2026 guidance and Glaukos’ expanding ophthalmology platform. Zacks growth outlook article
- Neutral Sentiment: Glaukos’ latest quarterly results showed revenue growth of 49.6% year over year to $185.6 million and a smaller-than-expected loss of $0.14 per share. However, the company remains unprofitable, and its elevated valuation increases sensitivity to execution and future growth.
- Negative Sentiment: Director Gilbert H. Kliman sold 2,500 shares for approximately $475,000 at $190 per share, reducing his direct holdings by 6.26%. He still owned 37,406 shares after the transaction, making the sale a limited—but potentially cautionary—insider signal. SEC insider trading filing
Analyst Upgrades and Downgrades
GKOS has been the subject of several research analyst reports. UBS Group initiated coverage on shares of Glaukos in a research report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 price target for the company. Piper Sandler reiterated an “overweight” rating and issued a $195.00 price objective (up from $165.00) on shares of Glaukos in a report on Thursday, July 30th. Stifel Nicolaus boosted their price objective on Glaukos from $175.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Needham & Company LLC increased their target price on Glaukos from $150.00 to $201.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a report on Friday, July 17th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $178.08.
Glaukos Price Performance
The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04. The stock’s 50 day simple moving average is $156.20 and its two-hundred day simple moving average is $131.24. The firm has a market capitalization of $10.99 billion, a PE ratio of -57.31 and a beta of 0.78.
Glaukos (NYSE:GKOS – Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The business had revenue of $185.61 million for the quarter, compared to analysts’ expectations of $150.93 million. During the same period in the previous year, the firm posted ($0.24) EPS. The business’s revenue for the quarter was up 49.6% compared to the same quarter last year. On average, sell-side analysts forecast that Glaukos Corporation will post -0.35 EPS for the current year.
Insider Buying and Selling
In other Glaukos news, Director Gilbert H. Kliman sold 2,500 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total value of $475,000.00. Following the completion of the sale, the director directly owned 37,406 shares of the company’s stock, valued at $7,107,140. This trade represents a 6.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Alex R. Thurman sold 20,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $180.13, for a total transaction of $3,602,600.00. Following the transaction, the chief financial officer directly owned 43,906 shares in the company, valued at approximately $7,908,787.78. The trade was a 31.30% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 113,025 shares of company stock valued at $19,600,006 over the last 90 days. Insiders own 5.90% of the company’s stock.
Hedge Funds Weigh In On Glaukos
Several institutional investors and hedge funds have recently bought and sold shares of GKOS. Stephens Inc. AR acquired a new stake in shares of Glaukos during the first quarter worth about $363,000. DNB Asset Management AS grew its holdings in shares of Glaukos by 11.9% in the fourth quarter. DNB Asset Management AS now owns 82,320 shares of the medical instruments supplier’s stock valued at $9,295,000 after purchasing an additional 8,770 shares in the last quarter. Quantinno Capital Management LP grew its holdings in shares of Glaukos by 964.0% in the first quarter. Quantinno Capital Management LP now owns 30,836 shares of the medical instruments supplier’s stock valued at $3,320,000 after purchasing an additional 27,938 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Glaukos by 209.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier’s stock worth $152,476,000 after buying an additional 913,458 shares during the period. Finally, Landscape Capital Management L.L.C. increased its stake in Glaukos by 125.3% during the 4th quarter. Landscape Capital Management L.L.C. now owns 23,017 shares of the medical instruments supplier’s stock worth $2,599,000 after buying an additional 12,799 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.
About Glaukos
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Read More
- Five stocks we like better than Glaukos
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
